Acadia Pharmaceuticals Inc (Nasdaq:ACAD), a developer of treatments for neurological and rare diseases, announced on Monday that the European Commission has granted marketing authorisation for DAYBU (trofinetide) to treat neurobehavioural symptoms of Rett syndrome in adults and children aged five and older.
This approval makes DAYBU the first and only treatment authorised for Rett syndrome in the European Union.
The decision was primarily supported by Phase 3 LAVENDER results, which showed statistically significant and clinically meaningful improvements in core Rett syndrome features based on the Rett Syndrome Behaviour Questionnaire (RSBQ) and Clinical Global Impression-Improvement (CGI-I) scale co-primary endpoints.
DAYBU is authorised for marketing across all 27 EU member states, as well as Iceland, Liechtenstein and Norway.
Acadia said it will begin pricing and reimbursement negotiations with national authorities as it works toward making the treatment available to patients across the region.
Acadia wins EU approval for DAYBU as first treatment for Rett syndrome
Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe
GSK's Jemperli wins FDA priority review for advanced rectal cancer
GSK secures first global approval for Hibsago in Japan
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
Rznomics joins Lilly Gateway Labs to accelerate RNA therapeutics
CureGene commences dosing in Phase I trial of CG-0416
Ipsen completes Kartos Therapeutics acquisition, strengthening late-stage oncology pipeline
Nuvation Bio's safusidenib granted FDA Fast Track Designation for IDH1-mutant glioma treatment